Sweden · Delayed Price · Currency is SEK Vitrolife AB Earnings Call Transcripts
Fiscal Year 2026
-
Record Consumables revenue and improved profitability driven by strategic exits and cost discipline. Gross margin and EBITDA margins rose across all regions, while market softness in China and the Middle East weighed on growth. Share repurchase and dividend programs were announced.
-
Organic growth reached 5% in local currencies, with strong North America and APAC performance offsetting Middle East declines. Gross margin hit 59.9%, and EBITDA margin was 31.1%. Innovation and restructuring are expected to further support profitability.
Fiscal Year 2025
-
Q4 saw 6% organic growth (excl. discontinued business), led by strong Americas and APAC performance, but margins declined due to currency and mix effects. A restructuring in Genetic Services and targeted campaigns shaped results, with 2026 expected to bring normalized market conditions and a focus on profitable growth.
-
Q3 saw 5% organic growth (excl. discontinued business) and strong cash flow, with Americas leading at 11% growth. Gross margin was stable at 58.9%, but currency headwinds and increased investments reduced EBITDA margin to 30.3%.
-
Q2 2025 delivered 3% organic growth (excl. discontinued), with strong share gains in consumables and genetics, but sales and margins were hit by currency headwinds and increased U.S. investment. Americas and EMEA outperformed their markets, while APAC remained flat due to weak cycles and delayed capital purchases.
-
EMEA and Americas delivered strong growth, offsetting APAC's sharp decline due to cultural cycle timing and tough comps. Gross margin improved, but EBITDA and net income declined year-over-year, mainly from FX and higher selling costs. Tariff and sanction risks are being managed through cost actions and selective price increases.
Fiscal Year 2024
-
Q4 2024 saw record sales and margins, driven by strong Consumables and Technologies growth, with operational efficiencies boosting profitability. Regional performance was mixed, and discontinued activities due to sanctions will have a gradual, neutral margin impact.
-
Q3 saw 7% organic growth in local currency, with strong gains in consumables and improved gross margin. Technologies and genetic services showed positive trends, though Genomic kits continued to decline. Management expects continued investment and steady progress toward long-term growth targets.
-
Gross margin rose to 59.9% and EBITDA margin to 34.7%, driven by strong product mix and operational improvements, especially in technologies and media. Market share gains were notable in North America and EMEA, while the acquisition of eFertility supports strategic platform integration.